ArticlePloS one2019
The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Trends and Opportunities in Tick-Borne Disease Geography.Journal of medical entomology · 2021Pooled it
- Clinical and economic outcomes evaluated in Lyme disease: a systematic review.Parasites & vectors · 2020Pooled it
- Efficacy of a low-dose fipronil bait in controlling blacklegged tick (Ixodes scapularis) larvae parasitizing white-footed mice (Peromyscus leucopus) under field conditions in the northeastern United States.Parasites & vectors · 2026Article
- Lessons Unlearned: The Barriers to Lyme Borreliosis Vaccination and the Risk of Repeating History.Vaccines · 2026Article
- A recombinase polymerase amplification lateral flow assay (RPA-LF) for detection of Babesia divergens-like parasites.Parasites & vectors · 2026Article
- Colonization of 3D-organotypic human skin by the Lyme Disease pathogen,bioRxiv : the preprint server for biology · 2026Article
- A framework for optimising arthropod DNA quality and quantity for modern sequencing tools using hard ticks (Ixodidae).Parasitology research · 2026Article
- Patient roadmap and economic burden of chronic tick-borne illness and post-treatment Lyme disease syndrome in Ireland, and public health issues arising.Frontiers in public health · 2026Article
- Reservoir host community and vector density predict human tick-borne diseases across the Eastern United States.Scientific reports · 2025Article
- Harnessing 50 years of tick population genetics: Choosing the right molecular tool for contemporary research.The Journal of animal ecology · 2025Review
- Molecular detection of Anaplasma Capra and Anaplasma marginale in Rhipicephalus microplus ticks infesting cows.Scientific reports · 2025Article
- 'You adapt, and you try not to resent it': a qualitative study exploring impacts of living with ticks and barriers to adopting preventive measures in Canada.BMC public health · 2025Article
- Tick spotting: using mannequins to evaluate individual efficacy at detecting Ixodes scapularis (Acari: Ixodidae).Journal of medical entomology · 2025Article
- Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review.New microbes and new infections · 2025Review
- Tick feeding or vaccination with tick antigens elicits immunity to theScience translational medicine · 2025Article
- Public health significance of the white-tailed deer (Odocoileus virginianus) and its role in the eco-epidemiology of tick- and mosquito-borne diseases in North America.Parasites & vectors · 2025Review
- Tick Control Strategies: Critical Insights into Chemical, Biological, Physical, and Integrated Approaches for Effective Hard Tick Management.Veterinary sciences · 2025Review
- Article
- The hypusine pathway inFrontiers in cellular and infection microbiology · 2025Article
- Understanding Ixodes ricinus occurrence in private yards: influence of yard and landscape features.International journal of health geographics · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionWhile Lyme disease (LD) is mostly treatable, misdiagnosed or untreated LD can result in debilitating sequelae and excessive healthcare usage. The objective of this review was to characterize the body of literature on the economic burden of Lyme disease (LD) and the cost-effectiveness of LD interventions, such as antibiotic treatment and vaccination.
methodsWe followed Joanna Briggs Institute scoping review methodologies. We systematically searched terms related to LD, economic evaluations, costs, and cost-effectiveness in Medline, Embase, PsycInfo, Cochrane Library, and the grey literature up to November 2017. We included primary economic evaluations conducted in North America and Europe, reporting LD-related costs or cost-effectiveness of human interventions. Two reviewers screened articles and charted data independently. Costs were standardized to 2017 United States dollars (USD).
resultsWe screened 923 articles, and included 10 cost-effectiveness analyses (CEA) and 11 cost analyses (CA). Three CEAs concluded LD vaccination was likely cost-effective only in endemic areas (probability of infection ≥1%). However, LD vaccination is not currently available as an intervention in the US or Europe. Six studies assessed economic burden from a societal perspective and estimated significant annual national economic impact of: 735,550 USD for Scotland (0.14 USD per capita, population = 5.40M), 142,562 USD in Sweden (0.014 USD per capita, 9.96M), 40.88M USD in Germany (0.51 USD per capita, 80.59M), 23.12M USD in the Netherlands (1.36 USD per capita, 17.08M), and up to 786M USD in the US (2.41 USD per capita, 326.63M).
conclusionsLyme disease imposes an economic burden that could be considered significant in the US and other developed countries to justify further research efforts in disease control and management. Societal costs for Lyme disease can be equally impactful as healthcare costs, but are not fully understood. Economic literature from countries with historically high incidence rates or increasing rates of Lyme disease are limited, and can be useful for future justification of resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.